Otonomy Reports Second Quarter 2016 Financial Results and Provides Corporate Update
04 août 2016 16h09 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients
01 août 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report Second Quarter 2016 Financial Results and Provide Corporate Update
28 juil. 2016 16h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 28, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO™ in Patients with Acute Otitis Externa
09 juin 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO™
20 mai 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 20, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces OTIPRIO™ Data Presentation and Symposium at Combined Otolaryngology Spring Meetings
16 mai 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update
09 mai 2016 16h15 HE
|
Otonomy, Inc.
SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at the Bank of America Merrill Lynch Healthcare Conference
05 mai 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease
23 mars 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 23, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Publication of OTIPRIO™ Phase 3 Clinical Trial Results in JAMA Otolaryngology
18 mars 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...